Halozyme Therapeutics stock rises as $1.3 billion convertible notes fuel growth guidance
Published on 09/22/2026 at 10:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Halozyme Therapeutics, Inc. stock (ISIN US40637H1095) is trading close to a new 52-week high after the biopharmaceutical company priced an upsized USD 1.3 billion offering of convertible senior notes due 2033 on September 17, 2026, a move that supports ambitious growth guidance for 2026 revenues and earnings. According to Yahoo Finance on September 22, 2026, the notes carry a 1.50 percent coupon and convert into stock at USD 139.84 per share, a 27.5 percent premium to the USD 109.68 closing price on September 17, while Halozyme guides to adjusted EBITDA growth near 90 percent in 2026.
Convertible notes deal underpins expansion plans
The key catalyst for Halozyme Therapeutics stock in mid-September 2026 is the company’s decision to tap the convertible debt market with a sizable upsized deal. As Yahoo Finance reports on September 22, 2026, Halozyme initially targeted USD 1.05 billion but increased the size of the convertible senior notes offering to USD 1.3 billion as investor demand came in strong, highlighting confidence in the company’s long-term growth story.
The structure of the notes is central to understanding both the opportunity and the risk for shareholders. According to Yahoo Finance, the notes pay 1.50 percent annual interest and are convertible into Halozyme shares at USD 139.84, which is 27.5 percent above the USD 109.68 closing price on September 17, 2026, while capped call transactions limit effective dilution up to USD 208.39 per share, roughly 90 percent above that same reference price.
Revenue guidance points to strong 2026 growth
Beyond financing, Halozyme is backing the note issuance with a clear top-line growth message for the current year. A biotech sector overview from RTTNews on September 21, 2026, notes that Halozyme expects full-year 2026 revenues to increase by 31 percent to 37 percent to a range of USD 1.83 billion to USD 1.91 billion, underscoring a double-digit expansion compared with the prior year’s level.
For investors, this revenue guidance provides a concrete yardstick. Assuming the midpoint of the range at USD 1.87 billion, a 34 percent increase implies that 2025 revenues were around USD 1.40 billion as a historical reference, which illustrates how quickly the company’s partnered drug delivery and auto-injector platforms are scaling. This comparison makes the near-90 percent adjusted EBITDA growth mentioned by Yahoo Finance especially notable, as profit growth is set to outpace revenue growth materially.
Short interest and valuation frame the risk-reward
While Halozyme Therapeutics stock benefits from strong growth expectations, the market’s positioning shows that not all investors are convinced. According to Yahoo Finance on September 22, 2026, Halozyme trades at a forward price-earnings multiple of 11.47 based on consensus expectations, a relatively modest valuation for a company guiding to adjusted EBITDA growth near 90 percent, while short interest stands at 17.19 percent of free float, indicating a sizable group of investors betting against the stock.
This combination of high expected earnings growth and elevated short interest can create volatility around catalysts such as earnings releases or major contract wins. If Halozyme delivers on its 31 percent to 37 percent revenue growth guidance for 2026 and converts that into the nearly 90 percent adjusted EBITDA increase highlighted by Yahoo Finance, the current forward price-earnings multiple of 11.47 would look conservative in hindsight; conversely, any disappointment against these aggressive targets could amplify downside pressure given the significant short positioning.
Stock trades at the top of its 52-week range
The recent price performance of Halozyme Therapeutics stock mirrors the fundamental optimism embedded in the company’s guidance and financing decisions. A real-time quote overview on Yahoo Finance shows that Halozyme shares closed at USD 112.45 on Nasdaq on September 18, 2026, up USD 2.77 or 2.53 percent from the previous close of USD 109.68, with the day’s trading range between USD 109.38 and USD 112.66.
Within the last 52 weeks, the stock has traded between a low of USD 61.23 and a high of USD 112.66, according to Yahoo Finance, meaning the September 18, 2026 closing price of USD 112.45 is effectively at the top of this range and roughly 83.6 percent above the 52-week low. For shareholders, this positioning near a fresh high signals that the market has already priced in a significant portion of the expected 2026 growth, limiting room for further re-rating unless guidance is raised or execution proves materially ahead of current forecasts.
Convertible structure and future earnings dates to watch
From a capital structure perspective, the USD 1.3 billion convertible notes give Halozyme flexibility to fund pipeline, partnerships and potential acquisitions while keeping near-term cash interest costs low. Yet the conversion level at USD 139.84 per share and the capped call ceiling at USD 208.39 per share, as detailed by Yahoo Finance, create a band within which future share price gains will eventually translate into dilution for existing shareholders.
Investors therefore have a clear set of levels to monitor over the coming quarters: if Halozyme Therapeutics stock moves significantly above the USD 139.84 conversion price on sustained fundamental strength, dilution becomes more than a theoretical consideration; if the shares break toward the USD 208.39 capped call upper boundary, the trade-off between leverage and equity issuance will be front and center in the valuation discussion. Until then, the relatively low 1.50 percent coupon and the planned 31 percent to 37 percent revenue growth for 2026, as described by RTTNews, suggest that management prefers to fund expansion through instruments that balance cost of capital with future equity flexibility.
Closing price context for Halozyme stock
As of the last completed trading day, Halozyme Therapeutics stock closed at USD 112.45 on Nasdaq on September 18, 2026, representing a 2.53 percent gain compared with the prior close of USD 109.68 and standing just USD 0.21 below the 52-week high of USD 112.66, based on data from Yahoo Finance. This price level near the top of the yearly range frames current investor expectations: strong revenue growth of 31 percent to 37 percent to USD 1.83 billion to USD 1.91 billion for 2026 and nearly 90 percent adjusted EBITDA growth, coupled with a forward price-earnings multiple of 11.47 and short interest around 17.19 percent of float, leave Halozyme positioned as a growth stock where execution against guidance and the impact of the USD 1.3 billion convertible notes will be decisive for the next leg of the share price move.
Halozyme Therapeutics stock facts
- Company: Halozyme Therapeutics, Inc.
- ISIN: US40637H1095
- Ticker: HALO
- Trading venue: Nasdaq
- Price (as of September 18, 2026, 4:00): 112.45 USD
- Market capitalization: [value not specified in available sources] USD (as of September 18, 2026)
- Sector / Industry: Biotechnology / Biopharmaceuticals
- Index membership: Nasdaq Composite
